Oncolink Features

Find My Cancer Drug

Tipos de Cancer / Cánceres de la Piel / Linfoma Cutáneo de Células T / Micosis Fungoides / Recursos de NCI

NCI CANCERLIT^® Search: Cutaneous T-cell Lymphoma - July 2002

Imprima English

National Cancer Institute^®
Ultima Vez Modificado: 1 de julio del 2002

Persistent pigmented purpuric eruption associated with mycosis fungoides: a case report and review of the literature.
Large-cell lymphoma. An unusual late relapse.
Denileukin diftitox for the treatment of panniculitic lymphoma.
Healing from the inside out: one person's path with cutaneous T-cell lymphoma--mycosis fungoides.
Trimetrexate in relapsed T-cell lymphoma with skin involvement.
Sarcomatoid variant of anaplastic large cell lymphoma mimicking a primary breast cancer: a challenging diagnosis.
Neutrophil-rich Ki-1-positive anaplastic large cell lymphoma: a study by fine-needle aspiration biopsy.
Functional inhibitory receptors expressed by a cutaneous T cell lymphoma-specific cytolytic clonal T cell population.
Treatment of cutaneous T-cell lymphoma with alitretinoin gel.
Mucin-poor follicular mycosis fungoides.
A case of hyper-IgE syndrome complicated by cutaneous, nodal, and liver peripheral T cell lymphomas.
Neurofibromatosis type 1 and mycosis fungoides.
Induction of complete remission of advanced stage mycosis fungoides by allogeneic hematopoietic stem cell transplantation.
Psoriasiform mycosis fungoides with fatal outcome after treatment with cyclosporine.
Mycosis fungoides and serology for human T-cell lymphotropic virus, type 1.
Effect of insulin-dependent diabetes mellitus on response to extracorporeal photopheresis in patients with Sezary syndrome.
[Mycosis fungoides. Study of a series of 11 Tunisian cases]
Cutaneous T-cell lymphoma/leukemia.
Angioimmunoblastic T-cell lymphoma with cutaneous involvement.
Therapy options in cutaneous T-cell lymphoma.
[Streptococcus pyogenes sepsis in a patient with Ki-1 anaplastic lymphoma]
Infrequent Fas mutations but no Bax or p53 mutations in early mycosis fungoides: a possible mechanism for the accumulation of malignant T

1
UI - 11451328
AU - Georgala S; Katoulis AC; Symeonidou S; Georgala C; Vayopoulos G
TI - Persistent pigmented purpuric eruption associated with mycosis fungoides: a case report and review of the literature.
SO - J Eur Acad Dermatol Venereol 2001 Jan;15(1):62-4
AD - National University of Athens, Department of Dermatology and Venereology, A. Sygros Hospital, Greece.
A purpuric eruption may be an unusual early manifestation of mycosis fungoides (MF). On the other hand, persistent pigmented purpuric dermatoses (PPPD) may, occasionally, evolve to cutaneous T-cell lymphoma. Coexistence of these two conditions has been reported, but it is extremely rare. We present the case of an elderly woman with a long-standing pruritic, pigmented purpuric eruption. On 1-year follow-up, histological features suggesting early MF were observed and molecular analysis of the rearrangement of T-cell receptor genes revealed clonality. Our patient may represent a case of PPPD evolving to MF, a case of MF clinically featuring PPPD, or an intermediate condition in a nosological continuity extending from PPPD to MF. A persistent pigmented purpuric eruption may rarely be a harbinger of cutaneous T-cell lymphoma. Therefore, vigilant long-term follow-up of PPPD is highly recommended.

2
UI - 11553063
AU - Bowles KM; Tooze R; Marcus RE
TI - Large-cell lymphoma. An unusual late relapse.
SO - Clin Lab Haematol 2001 Jun;23(3):197-9
AD - Department of Haematology, Addenbrookes Hospital, Cambridge, UK.
We report a case of a 40-year-old man with a stage 4, anaplastic, large-cell lymphoma. He had been diagnosed 13 years before as having a liposarcoma, at which point he was treated with combination chemotherapy, which included anthracycline. On review of the histopathology from 13 years before, the original diagnosis of liposarcoma was revised to that of an anaplastic large-cell lymphoma. A diagnosis of relapsed anaplastic large-cell lymphoma was made. A MUGA scan showed a reduced ejection fraction of 46%. Our patient responded initially to combination chemotherapy, which included anthracycline, without further reduction in his ejection fraction. This was followed by high-dose chemotherapy and peripheral blood stem-cell transplantation. Twenty months later he is well and remains in complete remission.

3
UI - 12056952
AU - McGinnis KS; Shapiro M; Junkins-Hopkins JM; Smith M; Lessin SR; Vittorio
TI - CC; Rook AH Denileukin diftitox for the treatment of panniculitic lymphoma.
SO - Arch Dermatol 2002 Jun;138(6):740-2
AD - arook@mail.med.upenn.edu

4
UI - 12056954
AU - Yudle L
TI - Healing from the inside out: one person's path with cutaneous T-cell lymphoma--mycosis fungoides.
SO - Arch Dermatol 2002 Jun;138(6):748-50
AD - leahyudle@yahoo.com

5
UI - 12065565
AU - Sarris AH; Phan A; Duvic M; Romaguera J; McLaughlin P; Mesina O; King K;
TI - Medeiros LJ; Rassidakis GZ; Samuels B; Cabanillas F Trimetrexate in relapsed T-cell lymphoma with skin involvement.
SO - J Clin Oncol 2002 Jun 15;20(12):2876-80
AD - Department of Lymphoma and Myeloma, University of Texas M.D. Anderson Cancer Center, Houston, TX, USA. a.sarris@hygeia.gr
PURPOSE: Methotrexate (MTX) is active against lymphomas, but transport or polyglutamylation mutations confer MTX resistance. Because trimetrexate (TMTX) enters cells by passive diffusion and is not polyglutamylated, its activity in relapsed T-cell lymphoma was investigated. PATIENTS AND METHODS: Eligible patients had histologically confirmed relapsed T-cell lymphoma involving the skin, had received more than one previous regimen, were older than 16 years, had normal organ function, and had no CNS disease or serious infections, including human immunodeficiency virus. TMTX (200 mg/m(2)) was given intravenously every 14 days without topical or systemic corticosteroids. Patients who responded received up to 12 doses. RESULTS: Twenty patients were assessable for response. Median age was 59 years (range, 45 to 87 years); 13 patients were men. Three patients had anaplastic large-cell lymphoma, 15 had mycosis fungoides or Sezary syndrome (14 with large-cell transformation), and two had peripheral T-cell lymphoma. Serum lactate dehydrogenase was high in 35%, and beta-2 microglobulin was more than 3.0 mg/L in 35% of patients. The median number of previous regimens was three (range, two to 15) and included MTX in five patients. Disease was refractory to the regimen immediately preceding TMTX in 85% of patients. Responses were complete in one and partial in eight patients (overall response rate, 45%). Two of five patients previously treated with MTX responded. Grade 3 or 4 mucositis was observed after 4%, infection after 3%, neutropenic fever after 6%, neutrophils less than 100/microL after 4%, and platelets less than 10,000/microL after 3% of TMTX doses. CONCLUSION: TMTX is active with acceptable toxicity in this population and merits further investigation.

6
UI - 12033965
AU - Pereira EM; Maeda SA; Reis-Filho JS
TI - Sarcomatoid variant of anaplastic large cell lymphoma mimicking a primary breast cancer: a challenging diagnosis.
SO - Arch Pathol Lab Med 2002 Jun;126(6):723-6
AD - Salomao & Zoppi Associated Pathologists, Porto, Portugal.
The sarcomatoid variant of anaplastic large cell lymphoma is one of the rarest histologic variants of this neoplasm. Due to its sarcomatoid features, it is frequently misdiagnosed as a poorly differentiated sarcoma, anaplastic carcinoma, or melanoma. We report the case of a 92-year-old woman with a sarcomatoid anaplastic large cell lymphoma mimicking a primary breast neoplasm. The patient presented with a rapidly enlarging lump in the left breast and nodules in the right axilla. The immunohistochemical profile showed reactivity for leukocyte common antigen, UCHL-1, vimentin, and CD30, but immunoexpression of anaplastic lymphoma kinase was lacking. Anaplastic large cell lymphomas are lymphoid neoplasms of T-cell/null-cell lineage that consistently express the activation marker CD30 and usually carry a gene rearrangement of the anaplastic lymphoma kinase gene. To the best of our knowledge, this is the first reported case of sarcomatoid anaplastic large cell lymphoma presenting as a primary breast neoplasm in which anaplastic lymphoma kinase expression was assessed.

7
UI - 12090418
AU - Creager AJ; Geisinger KR; Bergman S
TI - Neutrophil-rich Ki-1-positive anaplastic large cell lymphoma: a study by fine-needle aspiration biopsy.
SO - Am J Clin Pathol 2002 May;117(5):709-15
AD - Department of Pathology, Wake Forest University, Baptist Medical Center, Winston-Salem, NC, USA.
Fine-needle aspiration biopsy (FNAB) is an accurate, cost-effective method of evaluating lymphomas. The neutrophil-rich variant of anaplastic large cell lymphoma (NR-ALCL) is a rare non-Hodgkin lymphoma. To our knowledge, we present thefirst study of NR-ALCL by FNAB cytology. Histologic confirmation was available for both patients. Both cases were positive for Ki-1 (CD-30) and were either T-cell or null-cell phenotype. FNAB specimens were highly cellular with a single-cell pattern composed of pleomorphic tumor cells, "hallmark" tumor cells, and a background rich in neutrophils that occasionally obscured tumor cells. Diagnosis on FNAB is difficult owing to the rarity of this tumor, its resemblance to Hodgkin lymphoma and other non-Hodgkin lymphomas that express CD30, its similarity to an infectious process, and its occasional confusion with metastatic carcinoma and melanoma. Reproducible cytologic features usually are present, and the diagnosis can be made conclusively by FNAB in conjunction with ancillary studies.

8
UI - 11121132
AU - Bagot M; Martinvalet D; Echchakir H; Chabanette-Schirm F; Boumsell L;
TI - Bensussan A; Martinvallet D Functional inhibitory receptors expressed by a cutaneous T cell lymphoma-specific cytolytic clonal T cell population.
SO - J Invest Dermatol 2000 Dec;115(6):994-9
AD - INSERM U448, Paris XII University, Hopital Henri Mondor, AP-HP, Creteil, France. martine.bagot@hmn.ap-hop-paris.fr
Inhibitory receptors on natural killer cells and on a minority of T lymphocytes are major histocompatibility complex class Ia or Ib specific. We have previously reported several tumor-specific cytotoxic T cell clones infiltrating a CD4(+) V beta 13(+) cutaneous T cell lymphoma. These clones mediated a specific major histocompatibility complex class I-restricted cytotoxic activity toward the uncultured tumor cells and autologous long-term tumor T cell lines. In this study, we cultured with interleukin-2 the peripheral blood lymphocytes of the same patient a few weeks before invasion of the blood by tumor cells. We report the rapid and selective expansion of a CD8(+) V beta 13(+) lymphoid population. This population was clonal, as it expressed a unique T cell receptor-V beta junctional region. V beta 13(+) tumor cells and V beta 13(+) reactive T cells were shown to have different junctional sequences. The CD8(+) reactive clone was functional, as it had a specific autologous tumor-specific, human leukocyte antigen-A2 restricted, cytotoxic activity. This clone coexpressed high levels of CD158a, CD158b, p70, and CD94/NKG2A inhibitory receptors. Interestingly, we found that anti-CD158a and anti-CD158b monoclonal antibodies could inhibit anti-CD3 redirected cytotoxicity mediated by the reactive clonal population. Further, an anti-human leukocyte antigen-B/C monoclonal antibody enhanced the specific cytotoxic activity of the clone against autologous tumor cells. These results are the first evidence that inhibitory receptor expression can lead to the inhibition of cutaneous T cell lymphoma-specific T cell responses.

9
UI - 11982647
AU - Bassiri-Tehrani S; BA BA; Cohen DE
TI - Treatment of cutaneous T-cell lymphoma with alitretinoin gel.
SO - Int J Dermatol 2002 Feb;41(2):104-6
AD - Department of Dermatology, New York University School of Medicine, New York 10016, USA.

10
UI - 11982650
AU - Ozdemir M; Demirkesen C; Arzuhal N; Tuzun Y
TI - Mucin-poor follicular mycosis fungoides.
SO - Int J Dermatol 2002 Feb;41(2):112-4
AD - Department of Dermatology, Istanbul University Cerrahpasa Medical Faculty, Istanbul, Turkey. mustafaozdemir@yahoo.com

11
UI - 12081166
AU - Chang SE; Huh J; Choi JH; Sung KJ; Moon KC; Koh JK
TI - A case of hyper-IgE syndrome complicated by cutaneous, nodal, and liver peripheral T cell lymphomas.
SO - J Dermatol 2002 May;29(5):320-2

12
UI - 12031034
AU - Braam P; Sanders CJ; Canninga-Van Dijk MR
TI - Neurofibromatosis type 1 and mycosis fungoides.
SO - Int J Dermatol 2002 Apr;41(4):236-8
AD - Department of Dermatology, University Medical Center, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands.

13
UI - 12077596
AU - Masood N; Russell KJ; Olerud JE; Sabath DE; Sale GE; Doney KC; Flowers
TI - ME; Fefer A; Thompson JA Induction of complete remission of advanced stage mycosis fungoides by allogeneic hematopoietic stem cell transplantation.
SO - J Am Acad Dermatol 2002 Jul;47(1):140-5
AD - Fred Hutchinson Cancer Research Center, University of Washington School of Medicine, Seattle, WA 98109-1023, USA.
Advanced mycosis fungoides (MF) is incurable with conventional treatments. High-dose chemoradiotherapy with autologous bone marrow transplantation has induced remissions in a small number of patients with MF, but this modality is limited by a high relapse rate. We report induction of complete remission in a 37-year-old woman with rapidly progressive stage IV MF with allogeneic stem cell transplantation (Allo SCT). She remains in continuous complete remission 2 years after transplant. Allo SCT for MF is theoretically attractive, because there is no contamination of the graft by malignant cells, and because of the possibility of graft-versus-tumor effect. Although the results in this patient are encouraging, more patients and longer follow-up are needed to define the usefulness of Allo SCT in the treatment of MF.

14
UI - 12077599
AU - Zackheim HS; Koo J; LeBoit PE; McCalmont TH; Bowman PH; Kashani-Sabet M;
TI - Jones C; Zehnder J Psoriasiform mycosis fungoides with fatal outcome after treatment with cyclosporine.
SO - J Am Acad Dermatol 2002 Jul;47(1):155-7

15
UI - 12077602
AU - Kimball AB; Turner ML
TI - Mycosis fungoides and serology for human T-cell lymphotropic virus, type 1.
SO - J Am Acad Dermatol 2002 Jul;47(1):159; discussion 159-60

16
UI - 12077583
AU - Bouwhuis SA; el-Azhary RA; Gibson LE; McEvoy MT; Pittelkow MR
TI - Effect of insulin-dependent diabetes mellitus on response to extracorporeal photopheresis in patients with Sezary syndrome.
SO - J Am Acad Dermatol 2002 Jul;47(1):63-7
AD - Department of Dermatology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA.
BACKGROUND: Extracorporeal photopheresis (ECP) has become a primary therapy for selected forms of cutaneous T-cell lymphoma, especially Sezary syndrome. Variability in response of patients with Sezary syndrome to ECP has been reported. OBJECTIVE: Our purpose was to determine whether underlying medical conditions influence the efficacy of ECP in patients with Sezary syndrome. METHODS: We retrospectively reviewed the medical records of 55 patients with Sezary syndrome who received ECP between 1987 and 2000. Efficacy criteria included decrease in Sezary cell count, erythroderma, lymphadenopathy, organomegaly, and pruritus. RESULTS: Thirty-four patients responded well and 10 patients responded partially to ECP; 11 patients had no response. Nine patients with no response to ECP had insulin-dependent diabetes mellitus (IDDM). IDDM was documented in only 2 patients with a good response and in no patients with a partial response to ECP. CONCLUSION: Patients with Sezary syndrome and IDDM typically respond poorly to the standard ECP treatment regimen.

17
UI - 12071044
AU - Fazaa B; Goucha S; Zermani R; Zeglaoui F; Zghal M; Kennou H; Mezni F;
TI - Ezzine N; Kharfi M; Mokhtar I; Ben Jilani S; Kamoun MR [Mycosis fungoides. Study of a series of 11 Tunisian cases]
SO - Tunis Med 2002 Jan;80(1):40-5
AD - Service de Dermatologie, Etablissement Publique de Sante Charles Nicolle, Tunis.
Mycosis fungoides is an epidermotropic cutaneous T lymphoma. It's a non Hodgkinian lymphoma. We report the results of a retrospective review of 11 mycosis fungoide seen during 22 years. The frequency of MF was about 39.3% among all cutaneous lymphoma. Six patients were male and 5 were female; the mean age was about 56 years. Mean delay between diagnostic and the first manifestation was about 25 months. All patients had the progressive form: 4 had infiltrate plaques and 7 were at the tumoral phase. Lymph nodes and medullar metastases were noted respectively in 1 and 2 cases. Treatment was mono or polychemotherapy associated in 6 cases with topical drug. Three patients died of their diseases According to our experience and after reviewed the literature, we notice that our patients are slightly younger without male predominance. The diagnostic was done tardily and this may explain the pejorative prognostic.

18
UI - 12057060
AU - Siegel RS; Kuzel TM
TI - Cutaneous T-cell lymphoma/leukemia.
SO - Curr Treat Options Oncol 2000 Apr;1(1):43-50
AD - Robert H. Lurie Comprehensive Cancer Center, Northwestern University Medical School, 676 N. St. Clair, Suite 850, Chicago, IL 60611, USA.
Effective treatment for cutaneous T-cell lymphomas (CTCL) requires an accurate and specific diagnosis based on the clinical presentation combined with evaluation of the histopathology, immunophenotyping, and gene rearrangement studies. Careful clinical and pathologic evaluation in centers familiar with the diverse forms of CTCL is most valuable for determining treatment options. The goals of treatment in mycosis fungoides (MF), which afflicts more than 50% of patients with CTCL, are the relief of symptoms and improvement in cosmetics. Despite some uncontrolled clinical trial results that have been reported to suggest "cures" in this disease, the general perception remains that this disease is not curable with standard therapies available today. Treatment is divided into topical (skin-directed) and systemic therapy. The most active systemic agent for the treatment of MF remains interferon-alpha, although many new modalities have recently been approved for the treatment of CTCL.

19
UI - 11843225
AU - Mahendran R; Grant JW; Hoggarth CE; Burrows NP
TI - Angioimmunoblastic T-cell lymphoma with cutaneous involvement.
SO - J Eur Acad Dermatol Venereol 2001 Nov;15(6):589-90

20
UI - 12113107
AU - Apisarnthanarax N; Duvic M
TI - Therapy options in cutaneous T-cell lymphoma.
SO - Expert Rev Anticancer Ther 2001 Oct;1(3):403-20
AD - Department of Dermatology, MD Anderson Cancer Center, 1515 Holcombe Boulevard, Box 434, Houston, TX 77030-4095, USA.
The treatment of cutaneous T-cell lymphoma (CTCL) is continually evolving, as new and emerging drugs are added to the growing arsenal of CTCL therapy. The availability of newly approved investigational therapies, such as bexarotene, denileukin diftitox (DAB389- IL2), monoclonal antibodies and novel chemotherapeutic agents, adds complexity to decisions on the management and treatment of CTCL patients. In formulating a treatment plan, therapeutic options are best approached through consideration of overall clinical staging (stage IA-IVB) and skin staging (T1-T4), which affect prognosis and the characteristics of each individual patient's disease. This article will present and discuss the optimal therapeutic agents for all clinical stages of CTCL patients, based on currently available and investigational agents.

21
UI - 11766294
AU - Dominguez JM; Alegre J; Iglesias D; Recio J; Fernandez de Sevilla T
TI - [Streptococcus pyogenes sepsis in a patient with Ki-1 anaplastic lymphoma]
SO - An Med Interna 2001 Oct;18(10):556-7

22
UI - 12060388
AU - Dereure O; Levi E; Vonderheid EC; Kadin ME
TI - Infrequent Fas mutations but no Bax or p53 mutations in early mycosis fungoides: a possible mechanism for the accumulation of malignant T lymphocytes in the skin.
SO - J Invest Dermatol 2002 Jun;118(6):949-56
AD - Department of Pathology, Beth Israel Deaconess Medical Center-Harvard Medical School, Boston, Massachusetts 02215, USA.
Mycosis fungoides (MF) is the most frequent manifestation of cutaneous T cell lymphoma but its cause and pathophysiology remain unclear. Because progression of lesions is characteristically slow, we hypothesized that mycosis fungoides originates from an accumulation of lymphocytes due to defective apoptosis of skin homing T lymphocytes. In this study, we investigate possible alterations of three molecules regulating apoptosis, i.e., Fas antigen, Bax, and p53, at the genomic level in skin lesions from 44 patients with MF, as Fas mediates one of two major pathways for apoptosis of activated T cells. Fas mutations were found in six patients using a polymerase chain reaction and single-strand conformational polymorphism method followed by cloning and sequencing of abnormal polymerase chain reaction products. The mutations predict for defective transmission of the death signal in three cases. Immunohistochemistry demonstrated the lack of Fas protein expression on dermal lymphocytes in one case with Fas gene mutation predicting for a truncated death domain, whereas Fas protein was expressed by dermal lymphocytes in the other investigated cases. By contrast, no mutations of Bax or p53 were found, whereas immunohistochemistry demonstrated increased p53 expression in the nucleus of basal keratinocytes above the neoplastic infiltrate in some MF cases. These results support the hypothesis that Fas defects may play a role in the pathogenesis of MF.

The above citations and abstracts reflect those newly added to CANCERLIT for the month and topic listed in the title. The citations have been retrieved from CANCERLIT using a predefined search strategy of indexed subject terms. Although the search strategy has been refined as best as possible, citations may appear that are not directly related to the topic, and occasionally relevant references may be omitted.

OncoLink I wish u knew...

Ms. Gambino talks about the complexity of cancer care and the need for patients and families to have help in navigating from diagnosis and treatment decisions to survivorship. Read more.

Cancer Types
Bone Cancer
Brain Tumors
Breast Cancer
Carcinoid Tumors
Endocrine System Cancers
Gastrointestinal Cancers
Gynecologic Cancers
Head and Neck Cancers
Leukemia
Lung Cancers
Lymphomas
Myelomas
Pediatric Cancers
Penile Cancer
Prostate Cancer
Sarcomas
Skin Cancers
Testicular Cancer
Thyroid Cancer
Urinary Tract Cancers
OncoLink Vet

Cancer Treatment
Biologic Therapy
Bone Marrow Transplants
Chemotherapy
Clinical Trials
Complementary Medicine
Gene Therapy
General Treatment Concerns
Hormone Therapy
PDT Center
Proton Therapy
Radiation Oncology
Surgical Oncology
Targeted Therapies
Vaccine Therapies

Cancer Support
Caregivers
Hospice Care and Bereavement
Nutrition and Cancer
Sexuality & Fertility
Side Effects
Support
Survivorship
Exercise and Cancer

Cancer Resources
Cancer News
OncoLink University
Nurses' Notes
Conferences
Newly Diagnosed Patients
Causes and Prevention
Legal and Financial Information for Patients
LGBT Resources
NCI Resources
Global Resources
Cancer Resource List
Resources for Young Adults

OncoLink Media Library
OncoLink TV
Book, Music and Video Reviews

Ask the Experts
Brown Bag Chat
Tracy's Corner

About OncoLink
About OncoLink
Giving to OncoLink
Contact Information
Usage Policy
Editorial Board
How to Partner with OncoLink
Link to OncoLink
Mission Statement

What's New RSS

Tipos de Cáncer

Tratamiento del Cáncer

Riesgo de concer y prevencion

Drogas de Cáncer

Lidiando con el Cáncer

Profesionales de la salud

Estudios Clínicos

Oncolink Features

Find My Cancer Drug

NCI CANCERLIT^® Search: Cutaneous T-cell Lymphoma - July 2002

Table of Contents

OncoLink I wish u knew...

Tipos de Cáncer

Tratamiento del Cáncer

Riesgo de concer y prevencion

Drogas de Cáncer

Lidiando con el Cáncer

Profesionales de la salud

Estudios Clínicos

Oncolink Features

Find My Cancer Drug

NCI CANCERLIT® Search: Cutaneous T-cell Lymphoma - July 2002

Table of Contents

OncoLink I wish u knew...

Find Your Cancer Drug - A

Find Your Cancer Drug - B

Find Your Cancer Drug - C

Find Your Cancer Drug - D

Find Your Cancer Drug - E

Find Your Cancer Drug - F

Find Your Cancer Drug - G

Find Your Cancer Drug - H

Find Your Cancer Drug - I

Find Your Cancer Drug - J

Find Your Cancer Drug - K

Find Your Cancer Drug - L

Find Your Cancer Drug - M

Find Your Cancer Drug - N

Find Your Cancer Drug - O

Find Your Cancer Drug - P

Find Your Cancer Drug - R

Find Your Cancer Drug - S

Find Your Cancer Drug - T

Find Your Cancer Drug - V

NCI CANCERLIT^® Search: Cutaneous T-cell Lymphoma - July 2002